We hypothesized, based on prior findings, that the odds of breast cancer for current versus never MHT users would be higher for ER+ and ER+/PR+ subtypes and the ER+/PR+/HER2- subtype than for the corresponding receptor-negative breast cancers. The gene discussed is ERBB2; the disease is breast carcinoma.